Back to directory

Centre de Référence de l'Amylose AL et autres maladies par dépôt d'immunoglobulines monoclonales

CHU Poitiers

AL Amyloidosis 1 Rare Subtype

Contact Information

Primary Contact

Elise Michelon

Clinical Research Assistant

Activity level

  • Patients per year135
  • New diagnoses per year20

Multidisciplinary team

  • HematologyOn-site
  • CardiologyOn-site
  • NephrologyOn-site
  • NeurologyOn-site
  • PathologyOn-site
Other specialists
GastroenterologyHepatologyPulmonologyPrimary CareRheumatologyOrthopaedicsGeneticistsGenetic counsellorsNuclear medicine specialistsRadiologistsTransplant programme - kidneyPalliative carePsychology / counsellingSocial work

Diagnostic capabilities

  • EchocardiographyOn-site
  • Cardiac MRI (CMR)On-site
  • Radionuclide imagingOn-site
  • Histopathology (Congo red)On-site
  • Amyloid typingOn-site
  • Genetic testingOn-site
  • Fat aspiration / labial gland biopsyOn-site
  • Organ biopsiesOn-site

Subtype expertise

  • ALYes
  • ATTRvNo
  • ATTRwtNo
  • AANo
Rare subtypes
Localised amyloidosis
Referral pathways

Co-management of ATTRwt with cardiology department, and ATTRv with neurology department. Diagnosis of all rare subtypes.

Treatment options

  • Chemotherapy (AL)Available on-site
  • TTR stabilizersAvailable via formal referral
  • RNA interferenceAvailable via formal referral
  • Antisense oligonucleotidesAvailable via formal referral
  • Stem cell transplantAvailable on-site
  • Heart transplantAvailable via formal referral
  • Kidney transplantAvailable on-site
  • Liver transplantAvailable via formal referral

Patient support services

Services offered
Psychosocial supportSocial workGenetic counsellingNutritional guidance (dietitian)Specialty pharmacyPatient support groupsPalliative careFinancial or access counselling

Networks & telemedicine

  • Telemedicine / virtual consultationNo
  • Part of a formal amyloidosis networkYes
  • Diagnostic services for other organisationsYes

Last confirmed: 29 April 2026

Listings are self-reported by each center and have not been independently verified by the International Society of Amyloidosis (ISA). Inclusion in this directory does not constitute certification, accreditation, or endorsement by ISA.